

THE RELATIONSHIP BETWEEN OBESITY AND DIABETES

Asatullayev Rustamjon Baxtiyarovich

Tirkasheva Noila Ergash qizi

Trainee Assistant at SAMARKAND STATE MEDICAL UNIVERSITY

Abstract: *The global rise in obesity has led to a corresponding increase in the prevalence of diabetes mellitus, particularly type 2 diabetes. The connection between these two metabolic disorders is multifactorial, involving complex interactions between genetic, hormonal, inflammatory, and behavioral factors. Obesity contributes to insulin resistance, impaired glucose tolerance, and chronic hyperglycemia, all of which play a pivotal role in the pathogenesis of diabetes. This paper discusses the pathophysiological mechanisms linking obesity to diabetes, epidemiological trends, clinical implications, and preventive strategies aimed at reducing the global burden of these interrelated diseases.*

Keywords: *obesity, diabetes mellitus, insulin resistance, metabolic syndrome, adipokines, prevention*

Introduction

Obesity and diabetes are two of the most pressing health challenges of the 21st century. According to the World Health Organization (WHO), more than 1 billion adults worldwide are overweight, and over 650 million of them are obese. Simultaneously, the number of individuals living with diabetes has reached over 500 million and continues to rise annually. The parallel growth of these conditions is not coincidental — obesity is considered one of the strongest risk factors for developing type 2 diabetes mellitus (T2DM). The relationship between obesity and diabetes is so tight that the term “diabesity” has been introduced to emphasize their coexistence and mutual reinforcement. In the majority of patients with T2DM, obesity precedes hyperglycemia by several years, indicating that excess adipose tissue initiates metabolic changes leading to insulin resistance and β -cell dysfunction.

Pathophysiological Mechanisms Linking Obesity and Diabetes

The pathogenesis of diabetes in obese individuals is primarily mediated through insulin resistance and pancreatic β -cell failure. Adipose tissue is not merely a passive energy store; it functions as an active endocrine organ that secretes hormones (adipokines) and inflammatory cytokines that regulate energy balance and metabolism. Excess accumulation of visceral fat leads to elevated levels of free fatty acids (FFAs), TNF- α , IL-6, and resistin, all of which interfere with insulin signaling pathways. Concurrently, the secretion of beneficial adipokines such as adiponectin decreases, resulting in reduced insulin sensitivity.

This chronic low-grade inflammatory state promotes endothelial dysfunction, hepatic steatosis, and mitochondrial oxidative stress, ultimately impairing glucose uptake and promoting hyperglycemia. Furthermore, obesity-induced lipotoxicity damages pancreatic β -cells, reducing their capacity to secrete insulin in response to glucose stimulation. Over time, this imbalance between insulin demand and production results in persistent hyperglycemia and overt diabetes.

Epidemiology and Global Trends

Epidemiological data consistently show that the prevalence of diabetes increases proportionally with body mass index (BMI). Individuals with a BMI ≥ 30 kg/m² have a five- to seven-fold higher risk of developing T2DM compared to those with normal BMI. Even modest weight gain in early adulthood is associated with a significant rise in diabetes risk later in life. The highest rates of obesity-related diabetes are observed in the Middle East, Southeast Asia, and parts of Eastern Europe, including Uzbekistan, where rapid urbanization, sedentary lifestyles, and changes in dietary patterns have led to increased caloric intake and reduced physical activity. Among women, the risk is particularly high due to hormonal fluctuations, pregnancies, and postmenopausal changes influencing fat distribution.

Clinical and Public Health Implications

The coexistence of obesity and diabetes exacerbates metabolic disturbances and accelerates the development of cardiovascular complications. Obese individuals with diabetes are more prone to hypertension, dyslipidemia, atherosclerosis, nonalcoholic fatty liver disease, and polycystic ovary syndrome (PCOS). Moreover, they experience reduced quality of life and increased mortality from cardiovascular causes. From a clinical standpoint, weight reduction remains the cornerstone of diabetes prevention and treatment. Studies demonstrate that losing just 5–10% of initial body weight can significantly improve insulin sensitivity, decrease fasting glucose, and lower HbA1c levels. However, sustained weight loss is difficult to achieve, highlighting the need for a multidisciplinary approach combining nutritional therapy, behavioral counseling, pharmacotherapy, and, in severe cases, bariatric surgery.

Prevention and Management Strategies

The cornerstone of prevention lies in lifestyle modification. A balanced diet rich in fiber, fruits, vegetables, whole grains, and lean proteins — combined with reduced intake of saturated fats and refined carbohydrates — is crucial. Regular physical activity enhances insulin sensitivity and helps maintain healthy body weight. Public health campaigns should target children and adolescents to instill healthy habits early in life. Pharmacological interventions include insulin sensitizers (metformin, thiazolidinediones), weight-loss

medications (orlistat, GLP-1 agonists such as semaglutide), and, in extreme cases, bariatric surgery, which not only results in significant weight loss but also leads to remission of diabetes in many patients. Recent research emphasizes the importance of a personalized approach, integrating genetic screening, microbiome analysis, and hormonal profiling to identify individuals at high risk and to tailor preventive or therapeutic strategies accordingly.

Conclusion

The relationship between obesity and diabetes is undeniable and deeply intertwined. Obesity serves as the primary trigger for insulin resistance and subsequent β -cell failure, which culminates in type 2 diabetes mellitus. The current global trends demonstrate that without effective intervention, the dual epidemic of obesity and diabetes will continue to rise, posing severe socioeconomic and healthcare challenges. Addressing this issue requires a comprehensive strategy that combines lifestyle modification, early screening, pharmacologic innovation, and public health policy reforms. Effective prevention and management of obesity can substantially reduce the global burden of diabetes, improve longevity, and enhance quality of life across populations.

References:

1. World Health Organization. Obesity and overweight: key facts. WHO, 2024.
2. American Diabetes Association. Standards of Medical Care in Diabetes – 2025. *Diabetes Care*. 2025;48(Suppl 1):S1-S188.
3. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. *Nature*. 2006;444:840-846.
4. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. *Gastroenterology*. 2007;132(6):2169-2180.
5. Frühbeck G, Catalán V, Rodríguez A, Gómez-Ambrosi J. Adiponectin–leptin ratio as a biomarker of adipose tissue inflammation. *J Physiol Biochem*. 2019;75:201-210.
6. Locke AE et al. Genetic studies of body mass index yield new insights for obesity biology. *Nature*. 2015;518:197-206.
7. Bhupathiraju SN, Hu FB. Epidemiology of obesity and diabetes and their cardiovascular consequences. *Circ Res*. 2016;118:1723-1735.
8. Eckel RH, Kahn SE, Ferrannini E, Goldfine AB. Obesity and type 2 diabetes: what can be unified and what needs to be individualized? *J Clin Endocrinol Metab*. 2022;107(9):2579-2591.

9. Tamirisa K.P., Vaidya V.R., van Hagen I.M., et al. Metabolic risk factors in reproductive-age women with diabetes and obesity. *Int J Obstet Gynecol.* 2023;161:112-120.
10. WHO Global Report on Diabetes. Geneva: World Health Organization; 2023.
11. Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. *Lancet.* 2017;389:2239-2251.
12. Tam CS, Xie W, Johnson WD et al. Defining insulin resistance from obesity-related phenotypes. *Diabetes Care.* 2021;44:1738-1746.